The Latest Breakthroughs in mHSPC CME Available: https://auau.auanet.org/node/43825 After participating in this CME activity, participants will be able to: 1.Evaluate the concept of personalized therapy and its importance in the treatment of de novo mHSPC. 2.Implement current clinical guidelines for biomarker testing in mHSPC. 3.Explain the role of the PI3K/AKT pathway in prostate cancer biology. 4.Explore collaborations between urologists, oncologists, radiologists, and other healthcare professionals in managing de novo mHSPC. 5.Employ strategies to manage and mitigate common adverse events associated with AKT inhibitors and other therapies used in mHSPC. Acknowledgements: AstraZeneca Bayer HealthCare Pharmaceuticals Inc.
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
NPR News: 12-08-2025 2AM EST
08 Dec 2025
NPR News Now
NPR News: 12-07-2025 11PM EST
08 Dec 2025
NPR News Now
NPR News: 12-07-2025 10PM EST
08 Dec 2025
NPR News Now
Meidas Health: AAP President Strongly Pushes Back on Hepatitis B Vaccine Changes
08 Dec 2025
The MeidasTouch Podcast
Democrat Bobby Cole Discusses Race for Texas Governor
07 Dec 2025
The MeidasTouch Podcast
Fox News Crashes Out on Air Over Trump’s Rapid Fall
07 Dec 2025
The MeidasTouch Podcast